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Background: Proton-pump inhibitors such as omeprazole are a standard treatment to prevent non-steroidal anti-
inflammatory drug-induced upper gastrointestinal mucosal injuries. However, it is unclear which drugs may protect
against all NSAID-induced digestive-tract injuries. Here, we compare the efficacy of the gastromucoprotective drug
irsogladine with omeprazole in preventing NSAID-induced esophagitis, peptic ulcers, and small-intestinal mucosal
injury in healthy subjects.
Methods: Thirty-two healthy volunteers were assigned to an irsogladine group (Group I; n = 16) receiving
diclofenac sodium 75 mg and irsogladine 4 mg daily for 14 days, or an omeprazole group (Group O; n = 16)
receiving diclofenac sodium 75 mg and omeprazole 10 mg daily for 14 days. Esophagitis and peptic ulcers were
evaluated by esophagogastroduodenoscopy and small-intestinal injuries by capsule endoscopy, fecal calprotectin,
and fecal occult blood before and after treatment.
Results: There was no significant difference between Group I and Group O with respect to the change in lesion score
in the esophagus, stomach, and duodenum before and after treatment.NSAID treatment significantly increased the
number of small intestinal mucosal breaks per subject by capsule endoscopic evaluation, from a basal level of 0.1 ± 0.3
up to 1.9 ± 2.0 lesions in Group O (p = 0.0002). In contrast, there were no significant changes in the mean number of
mucosal breaks before and after co-treatment in Group I (0.3 ± 0.8 to 0.5 ± 0.7, p = 0.62), and the between-group
difference was significant (p = 0.0040). Fecal calprotectin concentration, when the concentration before treatment was
defined as 1, was significantly increased both in Group O (from 1.0 ± 0.0 to 18.1 ± 37.1, p = 0.0002) and Group I (from
1.0 ± 0.0 to 6.0 ± 11.1, p = 0.0280); the degree of increase in Group O was significantly higher compared with that in
Group I (p<0.05). In addition, fecal occult blood levels increased significantly in Group O (p = 0.0018), but there was no
change in Group I (p = 1.0), and the between-group difference was significant (p = 0.0031).
Conclusion: Irsogladine protected against NSAID-induced mucosal injuries throughout the gastrointestinal tract, from
esophagus to small intestine, significantly better than omeprazole.
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Gastroduodenal mucosal lesions are a well-known ad-
verse effect of non-steroidal anti-inflammatory drugs
(NSAIDs) [1]. Recently, the serious problem of NSAID-
induced small-intestinal damage has become a topic of
great interest to gastroenterologists since capsule endos-
copy and balloon enteroscopy have become available for
the detection of small-intestinal lesions [2]. Recent stud-
ies have shown that 55–68% of patients taking NSAIDs
have some mucosal damage in the small intestine [3-5].
Such lesions are of great concern in clinical settings, and
methods for their treatment and prevention must be
devised as soon as possible. Proton-pump inhibitors
(PPIs) are a standard treatment for the prevention of
NSAID-induced upper gastrointestinal mucosal injuries.
However, it is not clear whether PPIs are effective in the
lower digestive tract, where there is no acid. Irsogladine
(2,4-diamino-6-[2,5-dichlorophenyl]-s-triazine), a drug
for the treatment of gastric ulcers that is widely used in
Japan, Korea and China, protects the gastric mucosa by
enhancing the mucosal integrity of the stomach through
the facilitation of gap-junctional intercellular communi-
cation [6]. Irsogladine also prevents the development of
intestinal lesions induced by indomethacin in rats [7].
Irsogladine can be expected to be effective not only in
the stomach but also in other parts of the digestive tract.
Previous studies on the prevention of NSAID-induced
digestive tract injuries by various drugs [8-10] have been
limited to the upper digestive tract or the small intestine
individually, and there have been no studies of the entire
digestive tract from the esophagus through the stomach,
duodenum, and small intestine. It would be of great
benefit if a single drug could be used to manage NSAID-
induced injuries of both the upper and lower digestive
tract. In the present study, we compared the efficacy of
irsogladine and omeprazole in preventing NSAIDs-
induced esophagitis, peptic ulcers, and small-intestinal
mucosal injury in healthy subjects by using multidimen-
sional assessment; that is, esophagastroduodenoscopic
evaluation, capsule endoscopic evaluation, fecal cal-
protectin concentration and occult fecal blood test.Methods
Subjects
The study of 32 healthy volunteers was conducted pro-
spectively from April to August 2010 at Osaka Medical
College Hospital. Subjects eligible for inclusion were
healthy adults who 1) were aged between 20 and 79 yearsof age at the time of obtaining consent, 2) had freely
given their fully informed consent based on their full un-
derstanding, and 3) had taken no medication during the
one-month period before the start of the study. The
exclusion criteria were 1) a history of peptic ulcer or
gastrointestinal bleeding, 2) significant hepatic, renal,
heart, or respiratory disease, 3) a history of gastrointes-
tinal surgery other than appendectomy, 4) oral use or
planned oral use of a drug other than an antiulcer drug,
5) alcohol or chemical dependency, 6) a history of intes-
tinal obstruction or suspected gastrointestinal obstruc-
tion on other tests, 7) a lack of consent to the surgery
required if the capsule endoscope was retained in the
body, and 8) a determination by the investigator, at his
discretion, that a subject was ineligible for participation
in the study for any other reason. All subjects received
oral and written explanation of the study prior to par-
ticipation and gave written informed consent. The study
was conducted in accordance with the Declaration of
Helsinki (1995) after the protocol had been approved by
the Ethics Review Committee of Osaka Medical College.Protocol
This was a prospective, randomized, study. Every day for
two weeks, the irsogladine group (Group I) received
diclofenac sodium 75 mg plus irsogladine maleate 4 mg,
and the omeprazole group (Group O) received diclofenac
sodium 75 mg plus omeprazole 10 mg. The dose of
diclofenac sodium was determined based on the dose ap-
proved by the Japanese Ministry of Health and Welfare
and the doses used in other clinical trials [8-10]. Generally,
the dosage of a PPI used for the prevention of NSAID-
induced gastric ulcers is half the dosage used for the
treatment of gastric ulcers in Japan. On this basis, we de-
termined that the appropriate dosage of omeprazole
should be 10 mg/day.
The subjects were assigned to either Group I or Group
O prior to the study. Bowel preparation, capsule endos-
copy with a PillCam™SB video capsule (Given Imaging,
Yoqneam, Israel) and image evaluation were conducted
as previously reported [11]. We conducted a preliminary
analysis of the results of these baseline capsule endos-
copy examinations to determine subject eligibility for
the remainder of the study. Images were analyzed with
the software program Rapid Reader 4 (Given Imaging).
Lesions were evaluated according to the Los Angeles
classification or the Lanza score [12] by esophagogas-
troduodenoscopy, and the number of small-intestinal
Figure 1 Example photographs by capsule endoscopy
(A) typical bleeding, (B) mucosal break, (C) reddish lesions.
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serum biochemistry, fecal occult blood, and fecal cal-
protectin before and after two weeks of treatment. A
diagnosis of Helicobacter pylori (H. pylori) infection was
confirmed by a blood antibody test at the beginning of
the trial.
Esophagogastroduodenoscopy
To standardize the reporting criteria for the endoscopic
findings, the two endoscopists (T. K. and E.U.) attended
each other’s endoscopic sessions before and regularly
during the trial.
Capsule endoscopy
Mucosal breaks in the small intestine were defined as le-
sions with slough surrounded by erythema, correspond-
ing to the grade 2 category of Goldstein et al. [4].
Typical examples of the bleeding, mucosal breaks and
reddish lesions found in this study are shown in
Figure 1A–C. Reddish lesions, such as reddened folds,
denuded areas, and petechiae, were grouped in a single
classification: reddened lesions. Mucosal breaks, red-
dened lesions and bleeding were identified and evaluated
by independent blinded reviewers as described below.
The number of mucosal breaks, reddened lesions and
sites of bleeding in the small intestine found at baseline
and post-treatment by capsule endoscopy was calculated
for each subject and compared between Groups I and O.
The percentage of subjects with at least one mucosal
break in each treatment group was also calculated.
Investigators who were to evaluate the results of cap-
sule endoscopy of the small intestine were required to
attend a standardized training session on the use of the
Given Diagnostic System. These two investigators (T.K.
and E.U.) independently assessed the capsule endoscopic
images under blinded conditions. Positive findings were
classified as either mucosal bleeding or mucosal injury.
If the two observers recorded different findings, they
discussed the case until they reached agreement.
Noninvasive tests of intestinal damage
Subjects collected a stool sample for determination of
fecal calprotectin as a measure of intestinal inflamma-
tion at baseline and the final visit. Stools were frozen
within 12 h of receipt and stored at −20°C for subse-
quent analysis with an enzyme-linked immunosorbent
assay kit (Immundiagnostik, Bensheim, Germany) as
previously described [13]. Results are expressed as mi-
crograms of calprotectin per gram of stool, and a cutoff
value of 50 μg/g stool was used, as recommended by the
manufacturer [14]. The fecal calprotectin value suffers
the problems of variation, so we determined to use the
fold increase after treatment when the calprotectin con-
centration before treatment was set to 1. Before and
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tetramethylbenzidine and guaiac tests by using occult
fecal blood slide kits from Shionogi Pharma (Osaka,
Japan). In both tests, the color intensity of the oxidation
product was assigned to one of three categories, +, ± or −,
and on this basis differences between before and after
treatment were denoted “exacerbation”, “invariable” or
“improvement”. The hemoglobin and transferrin antibody
tests for occult fecal blood were performed with an OC-
Micro analyzer (Eiken, Tokyo, Japan). Generally, fecal oc-
cult blood is influenced by the intake of meat, fish, bright
red, green or yellow vegetables, and so on. Therefore, we
explained to our subjects how these foods affect the re-
sults of the occult blood tests(the tetramethylbenzidine
test and the guaiac test), and suggested that they pay at-
tention to their food intake during the period 4 days prior
to the examination date.
Sample size
The sample size was based on our estimation of the pro-
portion of subjects that would be expected to exhibit
mucosal breaks at post-treatment by capsule endoscopy.
We estimated that the incidence of mucosal injuries
would be approximately 20% in the irsogladine group,
on the basis of a preliminary study by Niwa et al. [8]
showing that the incidence of NSAID-induced small-
intestinal lesions was lower in subjects on daily
rebamipide (20%) than in subjects on placebo (80%). In
rats, irsogladine suppresses indomethacin-induced small-
intestinal lesions as effectively as rebamipide [7]. In
addition, we estimated that the incidence of mucosal in-
juries would be approximately 70% in the control group,
because a recent study found small-intestinal lesions in
55–68% of subjects taking NSAIDs [3,4]. Thus, 15
subjects would need to be recruited to each group (30
subjects in total) for a chi-square test, a significance
level of 5% (two-sided), a power of 80%, and equal allo-
cation. On the assumption that two subjects would not
be able to complete the study, a minimum of 32 subjects
was required.
Randomization
A coordinator performed a simple fixed-allocation ran-
domization by using a block-randomization scheme.
Random numbers were generated by SAS (SAS Institute,
Cary, NC, USA).
Statistics
For continuous or categorical variables, the statistical
significance of differences between groups was deter-
mined with the t test or Wilcoxon rank-sum test, and
the statistical significance of differences within a group
was determined with the Wilcoxon signed-rank test. For
binary variables, the statistical significance of differencesbetween groups was determined with the chi-square test.
All reported p values are two-sided, and values of less
than 0.05 were considered to indicate statistically signifi-
cant differences. All statistical values were calculated




The 32 subjects were randomly assigned to either Group
I or Group O and underwent baseline esophagogas-
troduodenoscopy and capsule endoscopy. None of the
subjects had significant findings in the esophagus
through to the small intestine, and all 32 were consid-
ered eligible for the study. The characteristics of each
group’s subjects, including age, sex, H. pylori infection
status, fecal hemoglobin concentration, and the numbers
of mucosal breaks, reddened lesions and sites of bleed-
ing, are shown in Table 1.
Esophagogastroduodenoscopy
By the Los Angeles classification, no esophageal mucosal
injuries were observed in either group before or after
treatment. In both groups, all 16 subjects were grade O
(no mucosal breaks) both before and after treatment
(Table 2). There was no significant difference between
Group O (from 0.6 ± 0.9 to 1.5 ± 1.1) and Group I (from
0.5 ± 1.1 to 0.9 ± 1.0) in the gastric Lanza score either
before or after treatment (p = 0.20). A similar result was
obtained for the duodenal Lanza scores (Group O, 0.0 ±
0.0 to 0.4 ± 0.8; Group I, 0.0 ± 0.0 to 0.4 ± 0.9; p = 0.94)
(Table 2).
Capsule endoscopy
A significantly higher percentage of subjects in Group O
(81.3% (13/16)) had mucosal breaks after treatment than
in Group I (37.5% (6/16); p = 0.012). The increase in the
mean number of small-intestinal mucosal breaks per
subject from baseline to study end was significantly
greater in Group O (0.1 ± 0.3 to 1.9 ± 2.0, p = 0.0002)
than in Group I (0.3 ± 0.8 to 0.5 ± 0.7; , p = 0.62) ( p =
0.0040; Figure 2 and Table 3).; Figure 2 and Table 3).
There were no significant differences in the numbers of
reddened lesions or sites of bleeding per subject before
and after treatment (Table 3).
Fecal calprotectin
The fecal calprotectin concentration increased after
treatment in both groups (Group O: 2400 ± 4000 to
5000 ± 6700, Group I: 14000 ± 35000 to 19000 ±
21000). The median baseline fecal calprotectin concen-
tration increased significantly after treatment in both
groups. However, when the calprotectin concentration
before treatment was set to 1, the fold increase after








No. of subjects 16 16
Age (years) (mean ± SD) 25±4 25±4 NS
Sex (M/F) 10/6 11/5 NS
H. pylori infection status (+/−) 1/15 1/15 NS
Fecal hemoglobin concentration
(mg/dL) (mean ± SD)
14.1 ± 2.0 14.4 ± 1.2 NS
Number of mucosal breaks
(mean ± SD)
0.3 ± 0.8 0.1 ± 0.3 NS
Number of reddened lesions
(mean ± SD)
0.2 ± 0.4 0.6 ± 0.8 NS
Number of sites of bleeding
(mean ± SD)
0.0 ± 0.0 0.1 ± 0.3 NS
NS = not significant.
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to 18.1 ± 37.1, p = 0.0002) than in Group I (1.0 ± 0.0 to
6.0 ± 11.1, p = 0.028) ( p<0.05, Figure 3).Occult blood test of stool
As assessed by the tetramethylbenzidine test (Figure 4),
fecal occult blood was significantly increased in Group
O after treatment compared with before treatment (p =
0.0018), but there was no significant change in Group I
(p = 1.0), and there was a significant post-treatment dif-
ference between the groups(p = 0.0031). Similar results
were obtained with the guaiac test (Group I, exacerba-
tion 25.0% (4/16), invariable 56.3% (9/16), improvement
18.8% (3/16); Group O, exacerbation 81.3% (13/16), in-
variable 12.5% (2/16), improvement 6.3% (1/16) (p =Table 2 The Los Angeles classification and Lanza scores
at baseline and after treatment
Baseline Post-treatment p value1
Irsogladine group






0.5 ± 1.1 0.9 ± 1.0 NS
Lanza scores (duodenum)
(mean ± SD)
0.0 ± 0.0 0.4 ± 0.9 NS
Omeprazole group NS






0.6 ± 0.9 1.5 ± 1.1 NS
Lanza scores (duodenum)
(mean ± SD)
0.0 ± 0.0 0.4 ± 0.8 0.0049
1P-values are baseline versus post-treatment within groups.0.0031)). By contrast, the fecal occult blood test results
obtained by using an antibody to human hemoglobin
(Group I, 38.9 ± 13.0 to 35.5 ± 19.5 ng/mL; Group O,
30.8 ± 21.0 to 29.0 ± 24.0 ng/mL) or transferrin (Group I,
13.1 ± 8.0 to 10.9 ± 7.5 ng/mL; Group O, 2.9 ± 5.4 to 3.5 ±
4.7 ng/mL) showed no significant change after treatment
compared with before treatment in either group.
Tolerability
Neither irsogladine nor omeprazole produced any side
effects.
Discussion
Our study demonstrated that short-term administration
of irsogladine suppressed NSAID-induced mucosal
injuries from the esophagus to the small intestine more
effectively than omeprazole. This is the first trial to in-
clude a multidimensional assessment of whether a single
drug can protect against NSAID-induced lesions in the
entire digestive tract from the esophagus to the small
intestine.
In previous investigations of the effectiveness of gas-
troprotective drugs in the prevention of small-intestinal
mucosal injuries induced by NSAIDs in volunteers,
evaluation was based on capsule endoscopic findings
only [8-10], so that the full extent of small-intestinal
mucosal injury may not have been appreciated. The use
of the biochemical approach (fecal occult blood, cal-
protectin), in addition to capsule endoscopy, enabled a
higher-quality evaluation. In our study, the irsogladine
group showed a significantly smaller increase in the
number of small-intestinal mucosal injuries by capsule
endoscopy, fecal calprotectin, and fecal occult blood
compared with the omeprazole group. Irsogladine was
originally developed as a drug for the treatment of gas-
tric ulcers and so, as might be expected, we found no
significant differences in the esophagus, stomach and
duodenum compared with omeprazole. Previous reports
suggest that irsogladine exerts various actions, including
inhibiting the reduction of gastric mucosal blood flow
induced by diclofenac [15], the suppression of free-
radical production [16] and the facilitation of gap-
junctional intercellular communications [6].
Previous studies have shown that 55–68% of patients
taking NSAIDs and omeprazole have some mucosal
damage in the small intestine [3,4]. In the present study,
the development of lesions, including mucosal breaks,
was also not inhibited with omeprazole, with lesions
found in 81.3% of subjects in the omeprazole group. In
contrast, lesion development was significantly inhibited
in the irsogladine group. Prior reports suggest that the
activation of gap-junctional intercellular communication
by irsogladine leads to a significant decrease in the para-




























Figure 2 Mean mucosal breaks per subject at post-treatment



















Figure 3 Changes in calprotectin levels after two weeks’
treatment with irsogladine or omeprazole (mean ± SD).
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4 [17]. We have found that irsogladine increases mucus
secretion and significantly suppresses the decreased
mucus response to indomethacin, resulting in the sup-
pression of bacterial invasion as well as the up-
regulation of the expression of inducible nitric oxide
synthase [7]. The suppression of small-intestinal injuries
by irsogladine may be explained partly by the mainten-
ance of intestinal permeability and partly by the stimula-
tion of mucus secretion.
Although misoprostol lowers gastrointestinal compli-
cations caused by NSAIDs in addition to preventing
endoscopic gastroduodenal ulcers [9,18], it can causeTable 3 Number of small-intestinal lesions per subject by
capsule endoscopy at baseline and after treatment
Baseline Post-treatment p value1
Irsogladine group
Number of mucosal breaks
(mean ± SD)
0.3 ± 0.8 0.5 ± 0.7 NS
Number of reddened lesions
(mean ± SD)
0.2 ± 0.4 0.4 ± 0.6 NS
Number of sites of bleeding
(mean ± SD)
0.0 ± 0.0 0.2 ± 0.5 NS
Omeprazole group
Number of mucosal breaks
(mean ± SD)
0.1 ± 0.3 1.9 ± 2.0 0.0002
Number of reddened lesions
(mean ± SD)
0.6 ± 0.8 1.3 ± 1.7 NS
Number of sites of bleeding
(mean ± SD)
0.1 ± 0.3 0.3 ± 0.4 NS
1P-values are baseline versus post-treatment within groups.mild diarrhea at a dose of only 600 μg [9]. Therefore, a
drug which is safe for use in the prevention of NSAID-
induced enteropathy without any adverse gastrointes-
tinal effects is highly desirable. On irsogladine, not only
the present study but also a previous study found no
adverse drug reactions such as diarrhea or abdominal
pain [19].
PPIs are the standard treatment for the prevention of
NSAID-induced upper gastrointestinal mucosal injuries;
however, this study has shown that the PPI omeprazole
was ineffective in the lower digestive tract. Furthermore,
Wallace JL et al. reported that PPIs exacerbate NSAID-
induced small-intestinal mucosal injuries in experimentalFigure 4 Fecal occult blood after two weeks’ treatment with
irsogladine or omeprazole compared to baseline.
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duction in the proportion of Actinobacteria in the
jejunum [20], a finding that strongly suggests that the
dysbiosis induced by a PPI is a major contributing factor
to the increased susceptibility to NSAID-induced small-
intestinal injuries caused by enteric microflora.
The limitation of this study is that we did not include an
NSAID monotherapy group, because it would have been
ethically unacceptable to administer an NSAID without any
prophylactic medicine for gastric ulcer. Therefore, it is
unknown whether omeprazole exacerbated small-intestinal
lesions. Also, the usefulness of irsogladine is unclear in
patients with a history of peptic ulcer or gastrointestinal
bleeding when NSAIDs are administered because the study
focused on healthy subjects with a low risk of digestive-
tract injuries. Additionally, the study was performed in the
relatively short period of two weeks, so further study is
required to validate the long-term usefulness of irsogladine.
Conclusions
In conclusion, in healthy volunteers irsogladine did not
show significant differences from PPIs in the extent of
inhibition of lesion development in the esophagus, stom-
ach, and duodenum, but it did significantly inhibit lesion
development in the small intestine compared with PPIs.
Therefore irsogladine may be a useful drug in the situation
where patients with a low risk of upper digestive tract injur-
ies are administered NSAIDs, to protect the entire digestive
tract from the esophagus to the small intestine.
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